Association of Antifibrotic Dosing Patterns With Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis in Real-World Data Sources.
Among patients with IPF, antifibrotic dose reductions and discontinuations were common, likely due to poor drug tolerability, and disease progression occurred in a substantial proportion of patients in both cohorts, regardless of antifibrotic dosing strategy, highlighting the ongoing need for more effective and better-...